HARVARD BIOSCIENCE INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HARVARD BIOSCIENCE INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $116.18M | Mar 16, 2020 |
| FY2018 | Dec 31, 2018 | $33.86M | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $28.64M | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $31.52M | Mar 18, 2019 |
| FY2018 | Mar 31, 2018 | $26.76M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $21.65M | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $18.72M | Mar 18, 2019 |
| FY2018 | Jun 30, 2017 | $18.96M | Mar 18, 2019 |
| FY2018 | Mar 31, 2017 | $18.09M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $26.42M | Mar 16, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.55M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $94.14M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $112.25M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $113.34M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $118.90M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $102.10M | Mar 11, 2022 |
| FY2019 | Dec 31, 2019 | $30.97M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $27.42M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $29.58M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $28.20M | Mar 16, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.91M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $54.77M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $66.07M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $60.82M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $67.65M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $58.04M | Mar 11, 2022 |
| FY2019 | Dec 31, 2019 | $17.23M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $14.98M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $15.96M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $16.15M | Mar 16, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.70M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($12.41M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($3.42M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($9.52M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($288.0K) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($7.81M) | Mar 11, 2022 |
| FY2019 | Dec 31, 2019 | $550.0K | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($2.62M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($247.0K) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($2.37M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.58M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($6.21M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.89M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($6.93M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $2.07M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $221.0K | Mar 11, 2022 |
| FY2019 | Dec 31, 2019 | $1.63M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($1.37M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $228.0K | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($119.0K) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.83M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $10.41M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $11.76M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $12.33M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $10.80M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $8.69M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $10.72M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $10.99M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $5.65M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.39M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.73M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.44M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $14.03M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.26M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $9.33M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $8.05M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $2.88M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $1.06M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.38M | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.64M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.79M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.59M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.20M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.15M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.22M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $986.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $890.0K | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.07M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $126.64M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $137.37M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $145.36M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $162.34M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $156.25M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $164.87M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $168.61M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $109.35M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $107.77M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.34M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $63.30M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $64.29M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $73.14M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $78.94M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $79.57M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $83.18M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $85.89M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $28.45M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $35.57M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.73M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $63.34M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $73.07M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $72.22M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $83.40M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $76.68M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $81.69M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $82.72M | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | $80.90M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $72.20M | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.56M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $56.32M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $57.07M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $56.26M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $57.69M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $58.59M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $57.38M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $57.30M | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | $36.34M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $38.03M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($214.71M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($158.01M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($145.61M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($142.19M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($132.67M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($132.39M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($124.58M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($119.89M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($116.97M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($116.03M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.61M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.11M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $4.28M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.51M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $7.82M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $8.32M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $8.34M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $8.17M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $5.19M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.60M | Mar 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.87M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $36.96M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $36.56M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $46.82M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $48.33M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $48.01M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $53.82M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $60.80M | Mar 16, 2020 |
| FY2017 | Jan 31, 2018 | $11.90M | Mar 16, 2018 |
| FY2017 | Dec 31, 2017 | $11.90M | Mar 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 16, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2019 | Dec 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Mar 16, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 44.72M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 44.07M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 43.39M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 42.08M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 41.14M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 39.41M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 38.19M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | 37.38M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 35.02M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 34.44M | Mar 16, 2018 |